Russian mulls increase in state funding of drugs public procurements

17 November 2020
russia_roubles_rubles_money_big

The Russian government may consider increasing state funding for public procurements of drugs in the next several years, according to recent statements, made by an official spokesman of the federal government and some local media reports.

According to official statistics, the current state expenditures on the drugs procurements in Russia is by 5-6 times lower than in the majority of Western countries, which is considered as non-acceptable by many senior officials in the Russian federal government.

Despite the fact that since the beginning of the novel coronavirus pandemic the government has increased procurements of certain drugs (particularly those, which could be potentially recommended for COVID-19 treatment), the current volume of their supplies to the domestic market is still insufficient. The latter traditionally sparks serious criticism from representatives of local public and patients.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Pharmaceutical